Clinical Trial Update: Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating pioglitazone for delaying onset of mild cognitive impairment due to Alzheimer's disease; trial terminated with results posted in 2019 a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cognitive Impairment Due to Alzheimer Disease

Drugs mentioned

• PIOGLITAZONE (Pioglitazone)

Snippet

Sponsor: Takeda | Conditions: Mild Cognitive Impairment Due to Alzheimer's Disease | Phase 3 | Status: TERMINATED | Results posted: 2019-08-14